![David McAvoy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David McAvoy
Consejero General en TEVA PHARMACEUTICAL INDUSTRIES LIMITED .
Fortuna: 14 570 $ al 31/05/2024
Cargos activos de David McAvoy
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Consejero General | 01/03/2024 | - |
Villages of Indiana | Director/Miembro de la Junta | - | - |
Historial de carrera de David McAvoy
Antiguos cargos conocidos de David McAvoy.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
FRESH TRACKS THERAPEUTICS, INC. | Oficial de Cumplimiento | 01/01/2019 | 01/09/2023 |
Consejero General | 01/01/2019 | 01/09/2023 | |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Oficial de Cumplimiento | 31/08/2019 | - |
Consejero General | 31/08/2019 | - | |
Brickell Subsidiary, Inc.
![]() Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Oficial de Cumplimiento | 01/01/2019 | - |
Consejero General | 01/01/2019 | - | |
ENDOCYTE, INC. | Oficial de Cumplimiento | 01/01/2018 | - |
Consejero General | 01/01/2018 | - |
Formación de David McAvoy.
Indiana University | Graduate Degree |
University of Notre Dame | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 9 |
Israel | 2 |
Operativa
General Counsel | 5 |
Compliance Officer | 4 |
Graduate Degree | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
Empresas privadas | 4 |
---|---|
Endocyte, Inc.
![]() Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Villages of Indiana | |
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Brickell Subsidiary, Inc.
![]() Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
- Bolsa de valores
- Insiders
- David McAvoy
- Experiencia